Albumin fusion proteins
View Patent ↗The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention,as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
1. An albumin fusion protein comprising a serum cholinesterase polypeptide fused to an albumin polypeptide, wherein said serum cholinesterase polypeptide is selected from:
(a) a full-length serum cholinesterase;
(b) a mature serum cholinesterase; and
(c) a fragment of serum cholinesterase, wherein said fragment has serum cholinesterase activity;
and wherein said albumin polypeptide is selected from:
(i) a full-length albumin;
(ii) a mature albumin;
(iii) a fragment of albumin, wherein said fragment of albumin has the ability to prolong the serum half-life of the fused serum cholinesterase polypeptide compared to the unfused serum cholinesterase polypeptide;
(iv) a polypeptide consisting of an amino acid sequence at least 95% identical to SEQ ID NO:18, wherein said polypeptide has the ability to prolong the serum half-life of the fused serum cholinesterase polypeptide compared to the unfused serum cholinesterase polypeptide;
(v) amino acids 1 to 585 of SEQ ID NO:18; and
(vi) amino acids 1 to 387 of SEQ ID NO:18.
2. The albumin fusion protein of claim 1 , wherein said serum cholinesterase polypeptide is mature serum cholinesterase and said albumin polypeptide is full-length albumin.
3. The albumin fusion protein of claim 1 , wherein said serum cholinesterase polypeptide is full-length serum cholinesterase and said albumin polypeptide is mature albumin.
4. The albumin fusion protein of claim 1 , wherein said serum cholinesterase polypeptide is mature serum cholinesterase and said albumin polypeptide is mature albumin.
5. The albumin fusion protein of claim 1 , wherein said serum cholinesterase polypeptide is mature serum cholinesterase and said albumin polypeptide is a fragment of albumin.
6. The albumin fusion protein of claim 1 , wherein said serum cholinesterase polypeptide is a fragment of serum cholinesterase and said albumin polypeptide is mature albumin.
7. The albumin fusion protein of claim 1 , wherein said serum cholinesterase polypeptide is a fragment of serum cholinesterase and said albumin polypeptide is a fragment of albumin.
8. The albumin fusion protein of claim 1 ,wherein said albumin polypeptide is at least 99% identical to SEQ ID NO:18.
9. The albumin fusion protein of claim 1 , wherein said serum cholinesterase polypeptide is fused to the N-terminus of the albumin polypeptide.
10. The albumin fusion protein of claim 1 , wherein said serum cholinesterase polypeptide is fused to the C-terminus of the albumin polypeptide.
11. The albumin fusion protein of claim 1 , wherein said serum cholinesterase polypeptide is fused to the N-terminus and C-terminus of the albumin polypeptide.
12. The albumin fusion protein of claim 1 , further comprising a secretion leader sequence.
13. The albumin fusion protein of claim 1 , which is non-glycosylated.
14. The albumin fusion protein of claim 1 , which is expressed in yeast.
15. The albumin fusion protein of claim 14 , wherein said yeast is a Saccharomyces cerevisiae.
16. The albumin fusion protein of claim 14 , wherein said yeast is glycosylation deficient.
17. The albumin fusion protein of claim 14 , wherein said yeast is glycosylation and protease deficient.
18. The albumin fusion protein of claim 1 , which is expressed by a mammalian cell.
19. The albumin fusion protein of claim 18 , wherein said mammalian cell is a COS, CHO (Chinese Hamster Ovary), or NSO cell.
20. A composition comprising the albumin fusion protein of claim 1 , and a pharmaceutically acceptable carrier.
21. A kit comprising the composition of claim 20 .